Phase 3Active, not recruitingAge-related condition
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
A Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Study to Investigate the Efficacy and Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms (Hot Flashes) in Women With Stage 0 to 3 Hormone Receptor-positive Breast Cancer Who Are Receiving Adjuvant Endocrine Therapy
- Sponsor
- Astellas Pharma Global Development, Inc. (Industry)
- Enrollment
- 982 enrolled
- Conditions
- Hot Flashes
- Interventions
- Fezolinetant; Placebo; Tamoxifen; Aromatase inhibitor
- Ages
- adults, older adults
- Registry
- NCT06440967, CTIS2024-510719-31-00
Full record on ClinicalTrials.gov
From the registry
One of the standard treatments for women with breast cancer is hormone therapy, but this treatment can cause hot flashes. Hormone replacement therapy, or HRT, is most often prescribed for hot flashes for women in menopause but cannot be given to women on hormone therapy for breast cancer. Fezolinetant, an alternative to HRT, treats hot flashes for women in menopause. As hot flashes happen in the same way for women on hormone therapy for breast cancer, fezolinetant could help these women. In this study, women on hormone therapy for breast cancer who have moderate to severe hot flashes will take part. They will either take fezolinetant or a placebo to treat their hot flashes. The placebo looks like fezolinetant but doesn't have any medicine in it. The main aim of this study is to confirm if women who take fezolinetant have fewer hot flashes that are less severe compared to women who take the placebo. Women 18 years or older seeking treatment for hot flashes. They can take part in the study if they have an average of 7 or more moderate to severe hot flashes each day. They are having…
Primary outcomes
- Mean change from Baseline to Week 4 in the frequency of moderate to severe VMS
- Mean change from Baseline to Week 12 in the frequency of moderate to severe VMS
- Mean change from Baseline to Week 4 in the severity of moderate to severe VMS
- Mean change from Baseline to Week 12 in the severity of moderate to severe VMS
History
Study completion expected
Last registry update
Primary completion
Started
Registered